• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激素疗法用于绝经症状的一线管理:实用建议。

Hormone therapy for first-line management of menopausal symptoms: Practical recommendations.

作者信息

Palacios Santiago, Stevenson John C, Schaudig Katrin, Lukasiewicz Monika, Graziottin Alessandra

机构信息

1 Palacios' Institute of Women's Health, Madrid, Spain.

2 National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK.

出版信息

Womens Health (Lond). 2019 Jan-Dec;15:1745506519864009. doi: 10.1177/1745506519864009.

DOI:10.1177/1745506519864009
PMID:31378196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6683316/
Abstract

Hormone therapy use has undergone dramatic changes over the past 20 years. Widespread use of hormone therapy in the 1980s and 1990s came to an abrupt halt in the early 2000s after initial findings of the Women's Health Initiative trial were published and the study was terminated. Since then, much has been learned about the characteristics of women most likely to benefit from hormone therapy. There is general agreement that women younger than 60 years or who initiate hormone therapy within 10 years of menopause onset gain short-term benefit in terms of symptomatic relief and long-term benefit in terms of protection from chronic diseases that affect postmenopausal women. Despite accumulating evidence in support of hormone therapy for symptomatic menopausal women, the slow response by the medical community has led to a 'large and unnecessary burden of suffering' by women worldwide. Greater efforts are clearly needed to educate physicians and medical students about the pathophysiology of menopause and the role of hormone therapy in supporting women through the transition. This article provides a brief historical perspective of events that led to the backlash against hormone therapy, explores the current position of guideline groups, and provides practical recommendations to guide first-line management of symptomatic menopausal women.

摘要

在过去20年里,激素疗法的使用发生了巨大变化。20世纪80年代和90年代激素疗法被广泛使用,但在21世纪初,随着妇女健康倡议试验的初步结果公布且该研究终止,其使用戛然而止。从那时起,人们对最有可能从激素疗法中受益的女性特征有了更多了解。普遍认为,60岁以下或在绝经开始后10年内开始使用激素疗法的女性,在缓解症状方面有短期益处,在预防影响绝经后女性的慢性疾病方面有长期益处。尽管有越来越多的证据支持对有症状的绝经女性使用激素疗法,但医学界的反应迟缓导致全球女性承受了“巨大且不必要的痛苦负担”。显然需要做出更大努力,向医生和医学生传授绝经的病理生理学以及激素疗法在帮助女性度过这一转变期方面的作用。本文简要回顾了导致对激素疗法产生强烈反对的事件的历史背景,探讨了指南制定小组的当前立场,并提供了实用建议,以指导对有症状的绝经女性进行一线管理。

相似文献

1
Hormone therapy for first-line management of menopausal symptoms: Practical recommendations.激素疗法用于绝经症状的一线管理:实用建议。
Womens Health (Lond). 2019 Jan-Dec;15:1745506519864009. doi: 10.1177/1745506519864009.
2
Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.从绝经激素治疗的妇女健康倡议试验中吸取的教训。
Obstet Gynecol. 2013 Jan;121(1):172-6. doi: 10.1097/aog.0b013e31827a08c8.
3
Comparative cardiovascular effects of different progestins in menopause.不同孕激素在绝经后对心血管系统的比较影响
Int J Fertil Womens Med. 2001 Sep-Oct;46(5):248-56.
4
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement.绝经后妇女激素治疗原发性预防慢性病:美国预防服务工作组推荐声明。
JAMA. 2017 Dec 12;318(22):2224-2233. doi: 10.1001/jama.2017.18261.
5
Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause.回到未来:激素替代疗法作为绝经初期女性预防策略的一部分。
Atherosclerosis. 2016 Nov;254:282-290. doi: 10.1016/j.atherosclerosis.2016.10.005. Epub 2016 Oct 6.
6
What the future holds for women after menopause: where we have been, where we are, and where we want to go.绝经后女性的未来走向:我们的过去、现状与展望。
Climacteric. 2014 Dec;17 Suppl 2:12-7. doi: 10.3109/13697137.2014.944497. Epub 2014 Aug 27.
7
The menopause: benefits and risks of estrogen-progestogen replacement therapy.更年期:雌激素 - 孕激素替代疗法的益处与风险
Fertil Steril. 1982 Apr;37(4):457-74. doi: 10.1016/s0015-0282(16)46149-2.
8
[Hormone replacement therapy in menopause].[更年期的激素替代疗法]
Arq Bras Endocrinol Metabol. 2014 Mar;58(2):172-81. doi: 10.1590/0004-2730000003044.
9
Current trends in hormone replacement therapy.激素替代疗法的当前趋势
Saudi Med J. 2002 May;23(5):495-502.
10
Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.特邀评论:激素治疗的风险与益处——妇女健康倡议研究结果及绝经后雌激素时机假说
Am J Epidemiol. 2009 Jul 1;170(1):24-8. doi: 10.1093/aje/kwp113. Epub 2009 May 25.

引用本文的文献

1
Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system.与更年期症状激素替代疗法相关的精神科安全性:一项针对美国食品药品监督管理局不良事件报告系统的真实世界研究。
Front Psychiatry. 2025 Jun 27;16:1614087. doi: 10.3389/fpsyt.2025.1614087. eCollection 2025.
2
Associations between hormone therapy use and tau accumulation in brain regions vulnerable to Alzheimer's disease.激素治疗的使用与易患阿尔茨海默病的脑区中tau蛋白积累之间的关联。
Sci Adv. 2025 Mar 7;11(10):eadt1288. doi: 10.1126/sciadv.adt1288. Epub 2025 Mar 5.
3
Administration of Young Coconut ( L.) Juice Ameliorates Memory Impairment in a Menopausal Rat Model.给予青椰子汁可改善更年期大鼠模型的记忆障碍。
Diseases. 2024 Oct 12;12(10):250. doi: 10.3390/diseases12100250.
4
Enhancing health and therapeutic potential: innovations in the medicinal and pharmaceutical properties of soy bioactive compounds.增强健康和治疗潜力:大豆生物活性化合物的药用和制药特性创新
Front Pharmacol. 2024 Oct 3;15:1397872. doi: 10.3389/fphar.2024.1397872. eCollection 2024.
5
The evolving perspective of menopause management in the United Kingdom.英国对更年期管理的不断变化的观点。
Womens Health (Lond). 2024 Jan-Dec;20:17455057241288641. doi: 10.1177/17455057241288641.
6
Ovarian tissue cryopreservation and transplantation as a natural means to delay menopause.卵巢组织冻存与移植——一种自然延缓绝经的方法。
Arch Gynecol Obstet. 2024 Nov;310(5):2305-2313. doi: 10.1007/s00404-024-07752-3. Epub 2024 Sep 28.
7
Evaluation of the Potential Beneficial Effects of L. Extract Supplementation in Postmenopausal Discomfort.评价 L. 提取物补充剂对绝经后不适的潜在有益效果。
Nutrients. 2024 Aug 11;16(16):2651. doi: 10.3390/nu16162651.
8
Unraveling the Dynamics of Estrogen and Progesterone Signaling in the Endometrium: An Overview.解析雌激素和孕激素信号在内膜中的作用机制:概述。
Cells. 2024 Jul 23;13(15):1236. doi: 10.3390/cells13151236.
9
Midlife Women's Menopausal Transition Symptom Experience and Access to Medical and Integrative Health Care: Informing the Development of MENOGAP.中年女性的绝经过渡症状体验以及获得医疗和综合保健服务的情况:为MENOGAP项目的开展提供信息
Glob Adv Integr Med Health. 2024 Jul 30;13:27536130241268355. doi: 10.1177/27536130241268355. eCollection 2024 Jan-Dec.
10
Adrenarche-accompanied rise of adrenal sex steroid precursors prevents NAFLD in Young Female rats by converting into active androgens and inactivating hepatic Srebf1 signaling.肾上腺性发育伴随的肾上腺性激素前体升高可通过转化为活性雄激素和使肝 Srebf1 信号失活来预防年轻雌性大鼠的非酒精性脂肪性肝病。
BMC Genomics. 2024 Feb 19;25(1):190. doi: 10.1186/s12864-024-10107-6.

本文引用的文献

1
Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.绝经后激素治疗与芬兰阿尔茨海默病风险:全国病例对照研究。
BMJ. 2019 Mar 6;364:l665. doi: 10.1136/bmj.l665.
2
A systematic review and meta-regression analysis to examine the 'timing hypothesis' of hormone replacement therapy on mortality, coronary heart disease, and stroke.一项系统评价和Meta回归分析,以检验激素替代疗法对死亡率、冠心病和中风的“时间假说”。
Int J Cardiol Heart Vasc. 2019 Jan 18;22:123-131. doi: 10.1016/j.ijcha.2019.01.001. eCollection 2019 Mar.
3
Hormone replacement therapy and prevention of chronic conditions.激素替代疗法与慢性病预防。
Climacteric. 2019 Jun;22(3):303-306. doi: 10.1080/13697137.2018.1551347. Epub 2019 Jan 10.
4
Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency.原发性卵巢功能不全的雌激素剥夺与心血管疾病风险。
Fertil Steril. 2018 Apr;109(4):594-600.e1. doi: 10.1016/j.fertnstert.2017.11.035. Epub 2018 Mar 28.
5
Menopause and hormone replacement therapy: the 2017 Recommendations of the Italian Menopause Society.更年期与激素替代疗法:意大利更年期协会2017年建议
Minerva Ginecol. 2018 Feb;70(1):27-34. doi: 10.23736/S0026-4784.17.04151-X. Epub 2017 Oct 3.
6
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.绝经激素治疗与全因及特定病因长期死亡率:妇女健康倡议随机试验
JAMA. 2017 Sep 12;318(10):927-938. doi: 10.1001/jama.2017.11217.
7
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.美国临床内分泌医师协会和美国内分泌学会关于绝经的立场声明 - 2017年更新版
Endocr Pract. 2017 Jul;23(7):869-880. doi: 10.4158/EP171828.PS.
8
The 2017 hormone therapy position statement of The North American Menopause Society.北美更年期协会2017年激素治疗立场声明。
Menopause. 2017 Jul;24(7):728-753. doi: 10.1097/GME.0000000000000921.
9
Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study.各种类型的绝经激素治疗与卒中风险:一项全国性队列研究。
Stroke. 2017 Aug;48(8):2266-2269. doi: 10.1161/STROKEAHA.117.017132. Epub 2017 Jun 16.
10
Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases?绝经期血管舒缩症状:心血管疾病风险和其他慢性疾病的生物标志物?
Climacteric. 2017 Aug;20(4):306-312. doi: 10.1080/13697137.2017.1315089. Epub 2017 Apr 28.